Cancers of the head & neck最新文献

{"title":"Survival and associated factors among patients with oral squamous cell carcinoma (OSCC) in Mulago hospital, Kampala, Uganda.","authors":"Juliet Asio,&nbsp;Adriane Kamulegeya,&nbsp;Cecily Banura","doi":"10.1186/s41199-018-0036-6","DOIUrl":"https://doi.org/10.1186/s41199-018-0036-6","url":null,"abstract":"<p><strong>Background: </strong>Despite improvements in diagnosis and patient management, survival and prognostic factors of patients with oral squamous cell carcinoma (OSCC) remains largely unknown in most of Sub Saharan Africa.</p><p><strong>Objective: </strong>To establish survival and associated factors among patients with oral squamous cell carcinoma treated at Mulago Hospital Complex, Kampala.</p><p><strong>Methods: </strong>We conducted a retrospective cohort study among histologically confirmed oral squamous cell carcinoma (OSCC) patients seen at our centre from January 1st 2002 to December 31st 2011. Survival was analysed using Kaplan-Meier method and comparison between associated variables made using Log rank-test. Cox proportional hazards model was used to determine independent predictors of survival. <i>P</i>-values of less than 0.05 were considered statistically significant.</p><p><strong>Results: </strong>A total of 384 patients (229 males and 155 females) were included in this analysis. The overall mean age was 55.2 (SD 4.1) years. The 384 patients studied contributed a total of 399.17 person-years of follow-up. 111 deaths were observed, giving an overall death rate of 27.81 per 100 person-years [95% CI; 22.97-32.65]. The two-year and five-year survival rates were 43.6% (135/384) and 20.7% (50/384), respectively. Tumours arising from the lip had the best five-year survival rate (100%), while tumours arising from the floor of the mouth, alveolus and the gingiva had the worst prognosis with five-year survival rates of 0%, 0% and 15.9%, respectively. Independent predictors of survival were clinical stage (<i>p</i> = 0.001), poorly differentiated histo-pathological grade (<i>p</i> <  0.001), male gender (p = 0.001), age > 55 years at time of diagnosis (<i>p</i> = 0.02) and moderately differentiated histo-pathological grade (<i>p</i> = 0.027). However, tobacco & alcohol consumption, tumour location and treatment group were not associated with survival (<i>p</i> > 0.05).</p><p><strong>Conclusions: </strong>The five-year survival rate of OSCC was poor at 20.7%. Male gender, late clinical stage at presentation, poor histo-pathological types and advanced age were independent prognostic factors of survival. Early detection through screening and prompt treatment could improve survival.</p>","PeriodicalId":72518,"journal":{"name":"Cancers of the head & neck","volume":"3 ","pages":"9"},"PeriodicalIF":0.0,"publicationDate":"2018-10-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/s41199-018-0036-6","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37247321","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Locally advanced high-risk HPV related oropharyngeal squamous cell carcinoma (OPSCC); have we forgotten it is a different disease?","authors":"Nabil F Saba,&nbsp;Shuli Li,&nbsp;Zain A Hussain,&nbsp;Rathan Subramanian,&nbsp;Joseph A Califano,&nbsp;Christine H Chung","doi":"10.1186/s41199-018-0035-7","DOIUrl":"https://doi.org/10.1186/s41199-018-0035-7","url":null,"abstract":"<p><p>HPV related OPSCC has a distinct behavior and improved outcome. As immunotherapy has recently evolved into a new standard for advanced (SCCHN), trials for high-risk SCCHN have trended to encompass both HPV related and unrelated diseases. In this invited editorial, we question the wisdom of this approach and argue for the design of trials focused specifically on HPV related locally advanced oropharyngeal squamous cell carcinoma as a unique disease entity.</p>","PeriodicalId":72518,"journal":{"name":"Cancers of the head & neck","volume":"3 ","pages":"8"},"PeriodicalIF":0.0,"publicationDate":"2018-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/s41199-018-0035-7","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37247320","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Thyroid cancer risk in airline cockpit and cabin crew: a meta-analysis.","authors":"George S Liu, Austin Cook, Michael Richardson, Daniel Vail, F Christopher Holsinger, Ingrid Oakley-Girvan","doi":"10.1186/s41199-018-0034-8","DOIUrl":"10.1186/s41199-018-0034-8","url":null,"abstract":"<p><strong>Background: </strong>Airline crew are exposed to ionizing radiation as part of their occupation and have a documented increased risk of melanoma and cataracts. However, whether their occupation predisposes them to an increased risk of thyroid cancer is not established. The purpose of this systematic review and meta-analysis was to assess the risk of thyroid cancer in airline cockpit and cabin crew compared with the general population.</p><p><strong>Methods: </strong>The MEDLINE database accessed via PubMed and Cochrane Database were searched. We included cohort studies reporting the standardized incidence ratio (SIR) or standardized mortality ratio (SMR) of thyroid cancers in any flight-based occupation.</p><p><strong>Results: </strong>Of the 1777 citations retrieved in PubMed, eight studies with a total of 243,088 aircrew members and over 3,334,114 person-years of follow-up were included in this meta-analysis. No relevant studies were identified on Cochrane Database. The overall summary SIR of participants in any flight-based occupation was 1.11 (95% CI, 0.79-1.57; <i>p</i> = 0.613; 6 records). The summary SIR for cockpit crew was 1.21 (95% CI, 0.75-1.95; <i>p</i> = 0.383; 4 records) and the summary SIR for cabin crew was 1.00 (95% CI, 0.60-1.66; <i>p</i> = 0.646; 2 records). The overall summary standardized mortality ratio for airline crew was 1.19 (95% CI, 0.59-2.39; <i>p</i> = 0.773; 2 records).</p><p><strong>Conclusion: </strong>Airline crew were not found to have a significantly elevated risk of thyroid cancer incidence or mortality relative to the general population. Future research should capitalize on the growing occupational cohort dataset and employ innovative methods to quantify lifetime radiation exposure to further assess thyroid cancer risk in airline crew.</p>","PeriodicalId":72518,"journal":{"name":"Cancers of the head & neck","volume":"3 ","pages":"7"},"PeriodicalIF":0.0,"publicationDate":"2018-08-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6460828/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37247319","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Investigating adherence to Australian nutritional care guidelines in patients with head and neck cancer.","authors":"Sophie Hofto, Jessica Abbott, James E Jackson, Elisabeth Isenring","doi":"10.1186/s41199-018-0033-9","DOIUrl":"10.1186/s41199-018-0033-9","url":null,"abstract":"<p><strong>Background: </strong>Significant weight loss and malnutrition are common in patients with head and neck cancer, despite advances in treatment and development of evidenced-based guidelines. The aim of this study was to assess adherence to evidenced-based guidelines and investigate nutrition outcomes during and post radiation treatment in head and neck cancer patients.</p><p><strong>Methods: </strong>This was a two-year retrospective cohort study of 209 head and neck cancer patients (85% male) treated with ≥20 fractions of radiation (mean dose = 64.8 Gy delivered over 31.9 fractions) at an Australian tertiary hospital.</p><p><strong>Results: </strong>Regarding guideline adherences, 80% of patients were seen by a dietitian weekly during treatment and 62% of patients were seen bi-weekly for six-weeks post-treatment. Average weight loss was 6.7% during treatment and 10.3% three-months post treatment. At the end of treatment, oropharyngeal and oral cavity patients had lost the most weight (8.8, 10.9%), with skin cancer and laryngeal patients losing the least weight (4.8, 2.9%). Gastrostomy patients (<i>n</i> = 60) had their tube in-situ for an average of 150 days and lost an average of 7.7 kg (9.4%) during treatment and 11.5 kg (13.5%) from baseline to three-months post treatment. The number of malnourished patients increased from 15% at baseline to 56% at the end of treatment, decreasing to 30% three-months post treatment.</p><p><strong>Conclusions: </strong>Despite high adherence to evidenced-based guidelines, large discrepancies in weight loss and nutritional status between tumor sites was seen. This highlights the opportunity for further investigation of the relationship between tumor site, nutritional status and nutrition interventions, which may then influence future evidenced-based guidelines.</p>","PeriodicalId":72518,"journal":{"name":"Cancers of the head & neck","volume":"3 ","pages":"6"},"PeriodicalIF":0.0,"publicationDate":"2018-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6460524/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37247318","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Extracapsular extension is not a significant prognostic indicator in non-squamous cancers of the major salivary glands.","authors":"Shayan Cheraghlou,&nbsp;Phoebe K Yu,&nbsp;Michael D Otremba,&nbsp;Saral Mehra,&nbsp;Wendell G Yarbrough,&nbsp;Benjamin L Judson","doi":"10.1186/s41199-018-0032-x","DOIUrl":"https://doi.org/10.1186/s41199-018-0032-x","url":null,"abstract":"<p><strong>Background: </strong>Extracapsular extension (ECE) is a well-established prognostic feature in squamous cell cancers of the head and neck. Although some extrapolate data from mucosal head and neck cancer to include ECE as a high-risk feature in salivary gland cancers, data is lacking about ECE's prognostic value for these malignancies. We investigate whether ECE is a significant prognostic indicator in pathologic node-positive cancers of the major salivary glands.</p><p><strong>Methods: </strong>A retrospective study of adult salivary gland cancer cases diagnosed from 2004 to 2013 in the NCDB was conducted. Demographic, tumor, treatment, and survival variables were included in the study. Univariate Kaplan-Meier analyses, as well as multivariate Cox survival regressions were performed.</p><p><strong>Results: </strong>Positive ECE status was associated with significantly worse survival in salivary SCC (HR 1.687; <i>p</i> = 0.002) but not non-squamous salivary cancers (HR 1.000; <i>p</i> = 0.998) on multivariate analysis. While post-operative radiotherapy was not associated with improved survival for patients without high-risk adverse features (high grade or positive surgical margins), its use was associated with better survival for ECE-positive salivary SCC patients without one of these additional adverse features (HR 0.064; <i>p</i> = 0.010).</p><p><strong>Conclusions: </strong>Although ECE is a significant prognostic indicator in salivary SCC, its prognostic significance for non-squamous salivary cancers may be limited. Radiotherapy may improve survival in cases with at least one high-risk adverse feature: high grade; positive surgical margins; and for salivary SCC specifically, positive ECE status.</p>","PeriodicalId":72518,"journal":{"name":"Cancers of the head & neck","volume":"3 ","pages":"5"},"PeriodicalIF":0.0,"publicationDate":"2018-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/s41199-018-0032-x","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37247317","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sex differences in patients with high risk HPV-associated and HPV negative oropharyngeal and oral cavity squamous cell carcinomas.","authors":"Hong Li, Henry S Park, Heather A Osborn, Benjamin L Judson","doi":"10.1186/s41199-018-0031-y","DOIUrl":"10.1186/s41199-018-0031-y","url":null,"abstract":"<p><strong>Background: </strong>Human papilloma virus (HPV)-associated head and neck cancer is now recognized as a distinct clinical entity from HPV-negative tumors, which are primarily associated with tobacco and alcohol exposure.Little is known, however, about the behavior of HPV-associated oropharynx (OP) and oral cavity (OC) SCCs as two distinct cancers and how sex affects the overall survival (OS) in these two cancers. The objective of our study is to determine if sex is associated with overall survival (OS) in patients with high-risk human papillomavirus (HPV)-positive and HPV-negative squamous cell carcinomas (SCC) in the oropharynx and oral cavity sites.</p><p><strong>Methods: </strong>This is a retrospective cohort study using a national database. Data were extracted from the National Cancer Database (NCDB) of patients diagnosed with OP or OC SCC from 2010 to 2014. Univariate and multivariate survival analyses were conducted with chi-square tests, Kaplan-Meier estimates, log-rank tests, and Cox proportional hazards multivariable modeling.</p><p><strong>Results: </strong>A total of 30,707 patients (13,694 OP HPV-associated, 7933 OP HPV-, 1220 OC HPV-associated, 7860 OC HPV-) were identified. In all four groups, women tended to be older and have lower T and N clinical classification than men. Though there were no significant differences in OS between the sexes in OP HPV-associated cancers, female sex was associated with worse OS in OP HPV- cancers (HR: 1.15; 95% CI 1.04-1.28, <i>p</i> = 0.004), whereas it was associated with improved OS in OC HPV-associated and HPV- cancers (HPV-associated: HR: 0.71; 95% CI 0.50-0.99, <i>p</i> = 0.048; HPV-: HR: 0.87; 95% CI 0.78-0.95, <i>p</i> = 0.004).</p><p><strong>Conclusion: </strong>The effect of sex on OS in OC and OP SCC appears to vary based on tumor location and HPV status. While the source of this difference in prognostic association is unclear, it may be related to an emerging difference in the biology of HPV carcinogenesis in these locations.</p>","PeriodicalId":72518,"journal":{"name":"Cancers of the head & neck","volume":"3 ","pages":"4"},"PeriodicalIF":0.0,"publicationDate":"2018-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6460664/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37247316","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Targeting phosphoinositide 3-kinase (PI3K) in head and neck squamous cell carcinoma (HNSCC).","authors":"Kyungsuk Jung,&nbsp;Hyunseok Kang,&nbsp;Ranee Mehra","doi":"10.1186/s41199-018-0030-z","DOIUrl":"https://doi.org/10.1186/s41199-018-0030-z","url":null,"abstract":"<p><p>The landscape of head and neck squamous cell carcinoma (HNSCC) has been changing rapidly due to growing proportion of HPV-related disease and development of new therapeutic agents. At the same time, there has been a constant need for individually tailored treatment based on genetic biomarkers in order to optimize patient survival and alleviate treatment-related toxicities. In this regard, aberrations of PI3K pathway have important clinical implications in the treatment of HNSCC. They frequently constitute 'gain of function' mutations which trigger oncogenesis, and PI3K mutations can also lead to emergence of drug resistance after treatment with EGFR inhibitors. In this article, we review PI3K pathway as a target of treatment for HNSCC and summarize PI3K/mTOR inhibitors that are currently under clinical trials. In light of recent advancement of immune checkpoint inhibitors, consideration of PI3K inhibitors as potential immune modulators is also suggested.</p>","PeriodicalId":72518,"journal":{"name":"Cancers of the head & neck","volume":"3 ","pages":"3"},"PeriodicalIF":0.0,"publicationDate":"2018-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/s41199-018-0030-z","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37244792","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Response to R-CHOP in HPV-related squamous cell carcinoma of base of tongue: a case report.","authors":"Ting Martin Ma,&nbsp;Hyunseok Kang,&nbsp;Steven P Rowe,&nbsp;Ana P Kiess","doi":"10.1186/s41199-018-0028-6","DOIUrl":"https://doi.org/10.1186/s41199-018-0028-6","url":null,"abstract":"<p><strong>Background: </strong>Synchronous squamous cell carcinoma of the head and neck (HNSCC) and non-Hodgkin's lymphoma is a rare clinical scenario. It is unknown whether the R-CHOP chemotherapy for lymphoma would also be active against HNSCC. Herein, we present such a case and a review of the literature.</p><p><strong>Case presentation: </strong>A 64 year-old female presented with painless jaundice. CT demonstrated a retroperitoneal mass and pathology showed follicular lymphoma. A base-of-tongue HPV⁺ squamous cell carcinoma was found incidentally on staging CT. R-CHOP chemotherapy was initiated. After 3 cycles of R-CHOP the lymphoma had a complete metabolic response and, unexpectedly, the HNSCC also demonstrated excellent response. The patient received another 3 cycles followed by radiation to the HNSCC and to date is in remission for both cancers.</p><p><strong>Conclusions: </strong>This case highlights the exquisite sensitivity of HPV-related HNSCC, which should be taken into consideration in treatment prioritization of a concurrent diagnosis of a second cancer.</p>","PeriodicalId":72518,"journal":{"name":"Cancers of the head & neck","volume":"3 ","pages":"2"},"PeriodicalIF":0.0,"publicationDate":"2018-05-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/s41199-018-0028-6","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37244791","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predictors of circulating INTERLEUKIN-6 levels in head and neck cancer patients.","authors":"Sylvine Carrondo Cottin,&nbsp;Stéphane Turcotte,&nbsp;Pierre Douville,&nbsp;François Meyer,&nbsp;Isabelle Bairati","doi":"10.1186/s41199-018-0029-5","DOIUrl":"https://doi.org/10.1186/s41199-018-0029-5","url":null,"abstract":"<p><strong>Background: </strong>Circulating interleukin-6 (IL-6) improves outcome prediction for second primary cancer (SPC) in head and neck cancer (HNC) patients. This study aimed to identify factors associated with IL-6 serum levels in HNC patients.</p><p><strong>Methods: </strong>This study was conducted as part of a phase III chemoprevention trial. IL-6 was measured using chemiluminescent immunometric assay on pretreatment serum sample obtained from 527 stage I-II HNC patients. Patients' lifestyle habits, sociodemographic, medical and tumor characteristics were evaluated before radiation therapy (RT). Factors independently associated with IL-6 levels before RT were identified using multiple linear regression.</p><p><strong>Results: </strong>The median IL-6 serum level was 3.1 ng/L. In the multivariate analysis, eight factors were significantly associated (<i>p</i> < 0.05) with IL-6: age, gender, marital status, body mass index, tobacco consumption, comorbidities, Karnofsky Performance Status and HNC site. Smoking duration and lifetime pack-years were positively associated with IL-6 serum levels in a dose-response relationship (<i>p</i>-value for trend ≤0.03).</p><p><strong>Conclusions: </strong>Circulating IL-6 is a strong predictor of the occurrence of SPC in HNC patients. We identified eight factors independently associated with serum IL-6 levels in 527 stage I-II HNC patients.The dose-response relationship between lifetime smoking and IL-6 serum levels suggested a causal role of tobacco exposure on IL-6 production. Further studies are needed to establish whether the effect of tobacco exposure on SPC could be partly mediated by IL-6, a pro-inflammatory cytokine.</p>","PeriodicalId":72518,"journal":{"name":"Cancers of the head & neck","volume":"3 ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/s41199-018-0029-5","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36265158","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Optimal use of lenvatinib in the treatment of advanced thyroid cancer.","authors":"Shunji Takahashi,&nbsp;Naomi Kiyota,&nbsp;Makoto Tahara","doi":"10.1186/s41199-017-0026-0","DOIUrl":"10.1186/s41199-017-0026-0","url":null,"abstract":"<p><p>The development of orally active, multitargeted kinase inhibitors (MKIs) represents a significant advance in the treatment of progressive, metastatic thyroid cancer. Lenvatinib, an MKI targeting vascular endothelial growth factor receptor, fibroblast growth factor receptor, platelet-derived growth factor receptor, c-Kit, and RET, has shown efficacy in stabilizing previously progressive disease, with emerging evidence of a possible benefit in terms of overall survival. However, lenvatinib is associated with a side-effect profile similar to those of other MKIs that might affect the outcome of therapy. The aim of this review is to summarize the clinical efficacy and safety of MKIs in the treatment of advanced thyroid cancer in pivotal phase III trials. Common adverse events that may occur during lenvatinib therapy and their management are discussed, including conditions in which its administration should be temporarily withdrawn and resumed pending resolution of adverse events. We focus on data from a subanalysis of Japanese patients in the SELECT trial and in a post-marketing study in Japan. We suggest that lenvatinib is a valuable treatment option for advanced differentiated thyroid cancer. Monitoring and careful management of adverse events including supportive care are required to ensure continuation of therapy.</p>","PeriodicalId":72518,"journal":{"name":"Cancers of the head & neck","volume":"2 ","pages":"7"},"PeriodicalIF":0.0,"publicationDate":"2017-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/s41199-017-0026-0","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37244790","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}